The healthy adherer effect

Archives of Internal Medicine

Volumn 169, Issue 17, 2009, Pages 1635-1636

  Andersohn, Frank ^a   Willich, Stefan N ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE SODIUM;

CARDIOVASCULAR DISEASE; HUMAN; LETTER; METASTASIS; METHODOLOGY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 70349772605     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.324     Document Type: Letter

References (4)

1. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009;169(3):260-268.
2. The Central Bureau of Statistics (Israel). Statistical abstract of Israel 2008: deaths and mortality rates, by cause, sex and age (by ICD-10) (Table 3.31). http: //www.cbs.gov.il/engindex.htm. Accessed April 18, 2009.
3. Granger BB, Swedberg K, Ekman I, et al; CHARM Investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in theCHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005; 366(9502):2005-2011. (Pubitemid 41773375)
4. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.